| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| 50mg |
|
||
| Other Sizes |
| Targets |
STAT3
|
|---|---|
| ln Vitro |
HJC0416 hydrochloride, with IC50 values of 1.76 µM and 1.97 µM, respectively, inhibits the proliferation of both ER-positive and ER-negative (triple negative) breast cancer cells. AsPC1 and Panc-1, two pancreatic cancer cell lines, exhibit a strong antiproliferative impact against it, with IC50 values of 40 nM and 1.88 µM, respectively[1]. HJC0416 hydrochloride (1–10 µM; 48 hours) causes apoptosis and suppresses cell proliferation in MDA-MB-231 breast cancer cells, along with alterations in cellular morphology[1].The STAT3 promoter activity is reduced by about 51% in MDA-MB-231 cells transiently transfecting with the pSTAT3-Luc vector, but stattic (HY-13818) only reduces the STAT3 promoter activity by 39%[1]. Comparing HJC0416 hydrochloride (1–10 µM; 12 hours) to Stattic (HY-13818), it is equally effective in inhibiting the synthesis of STAT3 proteins and phosphorylation at the Tyr-705 site. In MDA-MB-231 cells, it also causes cleaved caspase-3 and downregulates cyclin D1 levels[1].
|
| ln Vivo |
In comparison to the control mice, the intraperitoneal injection of HJC0416 hydrochloride (10 mg/kg) results in a 67% reduction in tumor volume after 7 days. Likewise, at a dose of 100 mg/kg, HJC0416 hydrochloride (oral administration; 100 mg/kg; 14 days) likewise significantly lowers tumor volume by 46%. Tumor volume decrease seemed to be superior with the ip approach. It is particularly remarkable that, at a dose of 100 mg/kg, HJC0416 does not exhibit any discernible toxicity[1].
|
| Cell Assay |
Cell Cycle Analysis[1]
Cell Types: MDA- MB-231 breast cancer cells Tested Concentrations: 1-10 µM Incubation Duration: 48 hrs (hours) Experimental Results: Induced cell apoptosis in cancer cells. Apoptosis Analysis[1] Cell Types: MDA-MB-231 breast cancer cells Tested Concentrations: 1 µM; 5 µM; 10 µM Incubation Duration: 12 hrs (hours) Experimental Results: diminished p-STAT3 phosphorylation expression and cyclin D1 level. |
| Animal Protocol |
Animal/Disease Models: Mice with MDA-MB-231 cells[1]
Doses: 10 mg/kg (ip); 100 mg/kg (oral) Route of Administration: intraperitoneal (ip)injection, 7 days; oral administration, 14 days Experimental Results: demonstrated antitumor effects in the MDA-MB-231 triple-negative breast cancer murine xenograft model. |
| References |
| Molecular Formula |
C18H18CL2N2O4S
|
|---|---|
| Molecular Weight |
429.32
|
| Exact Mass |
428.036
|
| CAS # |
2415263-08-8
|
| Related CAS # |
HJC0416; 1617518-22-5
|
| PubChem CID |
146018923
|
| Appearance |
White to off-white solid powder
|
| Hydrogen Bond Donor Count |
3
|
| Hydrogen Bond Acceptor Count |
5
|
| Rotatable Bond Count |
6
|
| Heavy Atom Count |
27
|
| Complexity |
634
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
C1=CC(=CC2=C1C=CS2(=O)=O)NC(=O)C3=C(C=CC(=C3)Cl)OCCCN.Cl
|
| InChi Key |
YWFDTXJORDWLGD-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C18H17ClN2O4S.ClH/c19-13-3-5-16(25-8-1-7-20)15(10-13)18(22)21-14-4-2-12-6-9-26(23,24)17(12)11-14;/h2-6,9-11H,1,7-8,20H2,(H,21,22);1H
|
| Chemical Name |
2-(3-aminopropoxy)-5-chloro-N-(1,1-dioxo-1-benzothiophen-6-yl)benzamide;hydrochloride
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: (1). This product requires protection from light (avoid light exposure) during transportation and storage. (2). Please store this product in a sealed and protected environment (e.g. under nitrogen), avoid exposure to moisture. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO: ~100 mg/mL (~232.9 mM; with ultrasonication)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (5.82 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween-80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), Clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of DMSO stock solution (25.0 mg/mL) to 400 μL of PEG300 and mix well; then add 50 μL of Tween-80 and mix well; finally add 450 μL of physiological saline and adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (5.82 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), Clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of DMSO stock solution (25.0 mg/mL) to 900 μL of 20% SBE-β-CD saline and mix well. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. Solubility in Formulation 3: ≥ 2.5 mg/mL (5.82 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), Clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of DMSO stock solution (25.0 mg/mL) to 900 μL of corn oil and mix well. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.3293 mL | 11.6463 mL | 23.2926 mL | |
| 5 mM | 0.4659 mL | 2.3293 mL | 4.6585 mL | |
| 10 mM | 0.2329 mL | 1.1646 mL | 2.3293 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
